NCT06139653Completed
CardioBreathApp vs IMT in Heart Failure
Therapeutic Effects of CardioBreath Aplication Versus Inspiratory Muscle Training (IMT) on Vagal Cardiac Modulation, Pulse Wave Velocity Maximal Respiratory Pressures in Heart Failure Patients: Cross-over Randomized Control Trial
Source: ClinicalTrials.gov · Last updated 15 Aug 2025
Brief summary (registry, in English)
Heart failure (HF) is a systemic clinical syndrome defined as cardiac dysfunction, which causes inadequate blood supply to meet metabolic needs. One of the most expressive markers of HF is neurologic exacerbation, with expected sympathetic hyperactivation, increased activity of the renin-angiotensin-aldosterone system and elevation of vasopressin levels. These changes compensate the low cardiac output in the onset of ventricular dysfunction ensure a long term high blood perfusion pressure,though aggravate this dysfunction and contributes to the HF progression. There are evidences ofthe therapeutic effects of respiratory exercise techniques for HF patients. However, it demands new data for larger prescription and employment of these kind of exercises. Advanced technologies allowed the elaboration of the application for slow breathing CardioBreath. So far, it requires the possibility of comparison of their effects versus widely validated Inspiratory Muscle Trainig (IMT) on respiratory and cardiovascular outcomes in order to elucidate their specific benefits. In this way compare CardioBreath ® App versus IMT through a crossover randomized clinical trial design may elucidate the response effects of these interventions in these patients.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 15 (actual)
- First submitted
- 31 Aug 2023
- Start date
- 1 Dec 2023
- Primary completion date
- 20 Dec 2024
- Lead sponsor
- Instituto de Cardiologia do Rio Grande do Sul
- Diseases
- Heart failure
- NCT number
- NCT06139653
What you commit to
- Study type: Interventional
- Participants enrolled: 15
- From 1 Dec 2023 to the primary completion date, 20 Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Heart failure of congenital origin
- Valve disease.
Other
- active smoking
- BMI \<30
- Diagnosis of sleep apnea
Who the study is looking for
- Consecutive CHF patients in treatment at the outpatient clinic (Institute of Cardiology)
- Of both sexes
- Aged between 40 and 70 years
- And ejection fraction (EF) reduced (\<40%)
- Who have access to a mobile device with access to Internet.
Age in the registry: 40 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Cardiology Institute of Rio Grande do Sul Coordinator of this site? Confirm its status | Porto Alegre | Brazil | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.